Global Fibrate Drugs Market 10 Year Forecast Report 2024-2034, by Drug Type, by Product Type, by Distribution Channel and By Region
March 18, 2024 05:09 ET
|
Research and Markets
Dublin, March 18, 2024 (GLOBE NEWSWIRE) -- The "Global Fibrate Drugs Market by Drug Type, by Product Type, by Distribution Channel, and By Region" report has been added to ResearchAndMarkets.com's...
Statins Market Analysis Reveals Robust Growth Prospects with Rising Demand for Cardiovascular Solutions
January 25, 2024 06:15 ET
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Statins Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user,...
Atherosclerotic Cardiovascular Disease Market Set to Exhibit Growth by 2032, Driven by Advancements and Emerging Therapies
January 24, 2024 10:32 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Atherosclerotic Cardiovascular Disease (ASCVD) - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ...
Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering
June 04, 2020 07:00 ET
|
Esperion Therapeutics, Inc.
– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering – – Esperion Aims to Set New Industry Standard by Pricing NEXLIZET for Patient Affordability and Access with...
Esperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and Ezetimibe
June 26, 2017 16:05 ET
|
Esperion Therapeutics, Inc.
– Complementary, Non-statin, Oral Bempedoic Acid / Ezetimibe Combination Therapy Demonstrates 48% Lowering of LDL-C and Significant hsCRP Reduction with Potential for Lower Occurrence of...